OTCM
AIXN
, Last price
USD
Name
AiXin Life International Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AiXin Life International, Inc. develops, manufactures, markets, and sells healthcare, nutritional products, and wellness supplements in the People's Republic of China. The company operates through four segments: Direct Sales, Pharmacy, Hotel, and Manufacture and Sale. It offers herbs, greens, and traditional Chinese remedies; and functional products, such as weight management tools, probiotics, and foods and drinks; and rhino king, colostrum powder derived from goat’s milk, tong li ke, gammaoling granules, amoxicillin capsules, loratadine tablets, and fuyang granules. The company also engages in hotel business. It provides products manufactured by the company and purchased from third parties, as well as marketing and distribution services to other manufacturers and suppliers of healthcare products. The company sells its products through company-owned offices open to clients, pharmacies, direct marketing, e-commerce, exhibition events, conferences, and person-to-person marketing. The company is based in Chengdu, China.
Key people
Quanzhong Lin
Chairman of the Board, President, Chief Executive Officer · since 2017
Guolu Li
Chief Financial Officer · since 2017
Executive Vice President, Treasurer, Secretary · since 2017
Yuhua Zhu
Director · since 2019
Yao-Te Wang
Independent Director · since 2017
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||